ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,297.10
-0.21%
Dow Jones
39,869.38
0.00%
US Dollar vs MXN
16.6733
-0.04%
Brent Oil
83.045
-0.19%
Bitcoin
66,300.69
1.63%
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Immunovant Inc (IMVT)

  7. Immunovant Inc (IMVT) Noticias

IMVT

Immunovant (IMVT)

Immunovant Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:IMVT
FechaHoraFuenteTítuloSímboloCompañía
12/03/202406:30GlobeNewswire Inc.Immunovant Awarded U.S. Patent for IMVT-1402NASDAQ:IMVTImmunovant Inc
23/02/202415:21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMVTImmunovant Inc
14/02/202407:47Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:IMVTImmunovant Inc
12/02/202406:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IMVTImmunovant Inc
12/02/202406:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMVTImmunovant Inc
16/01/202406:29Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:IMVTImmunovant Inc
03/01/202407:00GlobeNewswire Inc.Immunovant to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:IMVTImmunovant Inc
20/12/202316:40Dow Jones NewsImmunovant Gets Positive Data From Graves' Disease Treatment TrialNASDAQ:IMVTImmunovant Inc
20/12/202315:30GlobeNewswire Inc.Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ DiseaseNASDAQ:IMVTImmunovant Inc
20/12/202315:30GlobeNewswire Inc.Immunovant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ DiseaseNASDAQ:IMVTImmunovant Inc
28/11/202306:00GlobeNewswire Inc.Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class PotentialNASDAQ:IMVTImmunovant Inc
28/11/202306:00GlobeNewswire Inc.Immunovant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class PotentialNASDAQ:IMVTImmunovant Inc
13/11/202307:00GlobeNewswire Inc.Immunovant to Present at Upcoming Investor ConferencesNASDAQ:IMVTImmunovant Inc
09/11/202307:49Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:IMVTImmunovant Inc
09/11/202306:00GlobeNewswire Inc.Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended September 30, 2023NASDAQ:IMVTImmunovant Inc
02/10/202315:52GlobeNewswire Inc.Immunovant Announces Closing of Upsized Common Stock Financing and Full Exercise of Underwriters’ Option to Purchase Additional SharesNASDAQ:IMVTImmunovant Inc
29/09/202315:48Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:IMVTImmunovant Inc
28/09/202305:09Edgar (US Regulatory)Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectusesNASDAQ:IMVTImmunovant Inc
27/09/202322:41GlobeNewswire Inc.Immunovant Announces Pricing of $450 Million Common Stock FinancingNASDAQ:IMVTImmunovant Inc
26/09/202316:18KR Market News장기간 고금리와 美 정부 폐쇄 우려로 월스트리트 하락NASDAQ:IMVTImmunovant Inc
26/09/202316:00GlobeNewswire Inc.Immunovant Announces Proposed Offering of $300 Million of Common StockNASDAQ:IMVTImmunovant Inc
26/09/202305:00GlobeNewswire Inc.Immunovant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD ResultsNASDAQ:IMVTImmunovant Inc
25/09/202322:01GlobeNewswire Inc.Immunovant to Host Conference Call and Webcast to Report Initial IMVT-1402 Phase 1 Results on September 26, 2023NASDAQ:IMVTImmunovant Inc
10/08/202306:00GlobeNewswire Inc.Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2023NASDAQ:IMVTImmunovant Inc
26/06/202306:36Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:IMVTImmunovant Inc
26/06/202306:27Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:IMVTImmunovant Inc
22/05/202310:50Dow Jones NewsImmunovant Shares Touch 52-Week High After FDA Green Lights IMVT-1402 StudyNASDAQ:IMVTImmunovant Inc
22/05/202306:12Edgar (US Regulatory)Annual Report (10-k)NASDAQ:IMVTImmunovant Inc
22/05/202306:03Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:IMVTImmunovant Inc
22/05/202306:00GlobeNewswire Inc.Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023NASDAQ:IMVTImmunovant Inc
 Showing the most relevant articles for your search:NASDAQ:IMVT

Su Consulta Reciente

TSX
SIL
SilverCrest Metals
ASX
ISS
ISS Group Ltd
COIN
TORUSD
NASDAQ
AAZDBXX
Jpmorgan Chase Bank Na P...
LSE
TCU
NASDAQ
CAVM
USOTC
DLAKF
Deutsche Lufthansa (QX)
USOTC
CIAFF
Champion Iron (QX)
USOTC
RIBT
RiceBran Technologies (PK)
EU
IMATI
21S Matic INAV
CEGG
NEOUSDT
NEO
ASX
XFN
S&P ASX 200 Futures Aoni...
UNSW3
VVTETH
VersoView
LSE
AF16
Citi Fun 29
LSE
KBA
Mcsi China Usd
ASX
PIENA
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados